These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25736912)

  • 1. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.
    Trappe RU; Choquet S; Dierickx D; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Tarella C; Shpilberg O; Sender M; Salles G; Morschhauser F; Jaccard A; Lamy T; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Leithäuser M; Schlattmann P; Anagnostopoulos I; Raphael M; Riess H; Leblond V; Oertel S;
    Am J Transplant; 2015 Apr; 15(4):1091-100. PubMed ID: 25736912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
    J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
    Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
    Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
    Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB
    Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
    Zimmermann H; Koenecke C; Dreyling MH; Pott C; Dührsen U; Hahn D; Meidenbauer N; Hauser IA; Rummel MJ; Wolf D; Heuser M; Schmidt C; Schlattmann P; Ritgen M; Siebert R; Oschlies I; Anagnostopoulos I; Trappe RU
    Leukemia; 2022 Oct; 36(10):2468-2478. PubMed ID: 35974101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
    Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
    Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
    Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
    Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
    Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series.
    Montanari F; Radeski D; Seshan V; Alobeid B; Bhagat G; O'Connor OA
    Br J Haematol; 2015 Nov; 171(4):491-500. PubMed ID: 26250758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
    González-Barca E; Capote FJ; Gómez-Codina J; Panizo C; Salar A; Sancho JM; López A; Briones J; Muñoz A; Encuentra M; Mercadal S; Domingo-Domenech E; de Sevilla AF;
    Ann Hematol; 2021 Apr; 100(4):1023-1029. PubMed ID: 32367180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
    Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
    J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
    Zimmermann H; Denecke T; Dreyling MH; Franzius C; Reinke P; Subklewe M; Amthauer H; Kneba M; Riess H; Trappe RU
    Transplantation; 2018 May; 102(5):868-875. PubMed ID: 29189632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab.
    Rossignol J; Terriou L; Robu D; Willekens C; Hivert B; Pascal L; Guieze R; Trappe R; Baillet C; Huglo D; Morschhauser F
    Am J Transplant; 2015 Jul; 15(7):1976-81. PubMed ID: 25868706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
    Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.